Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 13, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | 20,000 | |
| Jun 22, 2015 | SVP, Pharmacology & Biology | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | 22,500 | |
| Mar 20, 2015 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | 18,647 | |
| Mar 20, 2015 | VP, Legal & IP | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 2,500 | -- | 22,292 | |
| Jun 29, 2009 | Sr VP, Technical Operations | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $10.54 | 34,040 | |
| Oct 21, 2008 | Chief Operating Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $10.51 | 41,949 | |
| Aug 28, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $13.77 | 57,116 | |
| Jul 28, 2008 | Senior VP, Drug Development | Open market or private sale of non-derivative or derivative security | Form 4 | 2,500 | $15.08 | 59,616 | |
| Mar 04, 2008 | Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,500 | $9.74 | 833,618 | |
| Mar 04, 2008 | Director, Ten Percent Owner | Open market or private purchase of non-derivative or derivative security | Form 4 | 2,500 | $9.74 | 833,618 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.